Disease-modifying therapies alter gut microbial composition in MS. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Katz Sand, Ilana; Zhu, Yunjiao; Ntranos, Achilles; Clemente, Jose C.; Cekanaviciute, Egle; Brandstadter, Rachel; Crabtree-Hartman, Elizabeth; Singh, Sneha; Bencosme, Yadira; Debelius, Justine; Knight, Rob; Cree, Bruce A.C.; Baranzini, Sergio E.; Casaccia, Patrizia
• Is Part Of: Neurology. Volume 6:Issue 1(2019)
• Publication Date: 2019-01
• Subjects: Neuroimmunology -- Periodicals; Neurology -- Periodicals; 616.8
• DOI: 10.1212/NXI.0000000000000517
• Languages: English
• ISSNs: 2332-7812

Abstract

Abstract : Objective: To determine the effects of the disease-modifying therapies, glatiramer acetate (GA) and dimethyl fumarate (DMF), on the gut microbiota in patients with MS. Methods: Participants with relapsing MS who were either treatment-naive or treated with GA or DMF were recruited. Peripheral blood mononuclear cells were immunophenotyped. Bacterial DNA was extracted from stool, and amplicons targeting the V4 region of the bacterial/archaeal 16S rRNA gene were sequenced (Illumina MiSeq). Raw reads were clustered into Operational Taxonomic Units using the GreenGenes database. Differential abundance analysis was performed using linear discriminant analysis effect size. Phylogenetic investigation of communities by reconstruction of unobserved states was used to investigate changes to functional pathways resulting from differential taxon abundance. Results: One hundred sixty-eight participants were included (treatment-naive n = 75, DMF n = 33, and GA n = 60). Disease-modifying therapies were associated with changes in the fecal microbiota composition. Both therapies were associated with decreased relative abundance of the Lachnospiraceae and Veillonellaceae families. In addition, DMF was associated with decreased relative abundance of the phyla Firmicutes and Fusobacteria and the order Clostridiales and an increase in the phylum Bacteroidetes. Despite the different changes in bacterial taxa, there was an overlap between functional pathways affected by both therapies. Interpretation: Administration of GA or DMF is associated with differences in gut microbial composition in patients with MS. Because those changes affect critical metabolic pathways, we hypothesize that our findings may highlight mechanisms of pathophysiology and potential therapeutic intervention requiring further investigation.